YK-11
Half-Life (t½) PO: 6h
Formula C25H34O6
Molecular Weight 430.54 g/mol Pharmacological Mechanism Steroidal AR partial agonist + putative myostatin pathway inhibitor (follistatin upregulation). Banned by WADA. Hepatotoxicity signal at high doses; testosterone suppression similar to other SARMs at multi-week cycles.
Half-Life & Elimination Curve (PO: 6h) 100% 50% 25% 12.5% 0% 0h 0×t½ 6h 1×t½ 12h 2×t½ 18h 3×t½ 24h 4×t½ 30h 5×t½ 0×t½ (0h): 100% remaining 1×t½ (6h): 50% remaining 2×t½ (12h): 25% remaining 3×t½ (18h): 12.5% remaining 4×t½ (24h): 6.3% remaining 5×t½ (30h): 3.1% remaining Elimination (PO)
0×t½ 0h 100% 1×t½ 6h 50% 2×t½ 12h 25% 3×t½ 18h 12.5% 4×t½ 24h 6.3% 5×t½ 30h 3.1% Dosing Guidelines Oral (PO): Typical 10 mg (Range: 5–15 mg)Pathways It Modulates Target Organ Systems Endocrine System digestive Chemical Structure & Identifiers InChIKey: KCQHQCDHFVGNMK-PQUNLUOYSA-NSMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24/C(=C\C(=O)OC)/OC(O4)(C)OC)CCC5=CC(=O)CC[C@H]35Directory Compounds Registry Human Biology Hub